Compare Hims and Hers Health Inc (HIMS) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Nomura Holdings Inc — how do they compare? Hims and Hers Health Inc trades at $32.7 (market cap $7.57B), while Nomura Holdings Inc trades at $9.93 (market cap $27.46B). The key difference: Nomura Holdings Inc is far larger — about 3.6× Hims and Hers Health Inc's market cap, and Nomura Holdings Inc pays a 3.45% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.
| HIMS | NMR | |
|---|---|---|
Market Cap | $7.57B | $27.46B |
Sector | Health | Financials |
52-Week High | $66.18 | $10.04 |
52-Week Low | $14.52 | $6.39 |
Enterprise Value | $7.95B | — |
Dividend Yield | — | 3.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $32.70, down 0.43% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. Fundamentally, the company reported 2025 revenue of $2.35 billion and net income of $128.37 million, though 2026 projections indicate a net loss. Recent news highlights executive departures and anticipation for Q2 2026 earnings on August 10, 2026.
The investment outlook is cautiously optimistic, supported by a 35% analyst buy rating and a $33.57 consensus price target. Key opportunities include growth in the weight-loss drug segment and international expansion. Risks involve profitability volatility, intense competition, and reliance on telehealth regulatory frameworks. The stock's valuation remains elevated with a P/E of 57.14, demanding strong future earnings growth to justify current levels.
Nomura Holdings (NMR) trades at $9.81, up 4.36% with a bullish technical signal from moving averages. The company reported record annual profit of $340.74 billion for 2025, with revenue growing to $1.66 trillion and profit margin expanding to 20.49%. Recent news highlights strong wholesale revenue growth exceeding 30% and strategic acquisitions in US asset management. The stock trades at a P/E of 12.77, below industry averages, suggesting potential undervaluation.
Outlook remains positive with continued wholesale business momentum and global expansion initiatives. Key risks include integration costs from recent acquisitions and potential market volatility. Analyst consensus shows 33% buy ratings with no sell recommendations, indicating cautious optimism. The combination of reasonable valuation and strong fundamental performance supports potential upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
